Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against gram-negative clinical isolates in New York City

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4856-4860

  Lapuebla, Amabel ^a   Abdallah, Marie ^a   Olafisoye, Olawole ^a   Cortes, Christopher ^b   Urban, Carl ^b   Quale, John ^a   Landman, David ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; MEROPENEM; SINGLE HETEROCYCLIC RINGS; THIENAMYCIN DERIVATIVE; VABORBACTAM;

COMBINATION DRUG THERAPY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; NEW YORK; PROCEDURES;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BORONIC ACIDS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HETEROCYCLIC COMPOUNDS, 1-RING; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; NEW YORK CITY; THIENAMYCINS;

EID: 84939812571     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00843-15     Document Type: Article

References (22)

1. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. 2014. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. J Antimicrob Chemother 69: 1804-1814. http://dx.doi.org/10.1093/jac/dku048.
2. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791-1798. http://dx.doi.org/10.3201/eid1710.110655.
3. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471-3484. http://dx.doi.org/10.1128/AAC.01464-06.
4. Logan LK. 2012. Carbapenem-resistant Enterobacteriaceae: an emerging problem in children. Clin Infect Dis 55:852-859. http://dx.doi.org/10.1093/cid/cis543.
5. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50:1633-1641. http://dx.doi.org/10.1128/AAC.50.5.1633-1641.2006.
6. Bratu S, Landman D, Martin DA, Georgescu C, Quale J. 2008. Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother 52:2999-3005. http://dx.doi.org/10.1128/AAC.01684-07.
7. Toussaint KA, Gallagher JC. 2015. β-Lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 49:86-98. http://dx.doi.org/10.1177/1060028014556652.
8. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 17 March 2015. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases. J Med Chem http://dx.doi.org/10.1021/acs.jmedchem.5b00127.
9. Livermore DM, Mushtaq S. 2013. Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 68:1825-1831. http://dx.doi.org/10.1093/jac/dkt118.
10. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J. 2004. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 39:55-60. http://dx.doi.org/10.1086/421495.
13. Nordmann P, Poirel L. 2002. Emerging carbapenemases in Gramnegative aerobes. Clin Microbiol Infect 8:321-331. http://dx.doi.org/10.1046/j.1469-0691.2002.00401.x.
14. Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15-22. http://dx.doi.org/10.1128/AAC.48.1.15-22.2004.
15. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27:351-353. http://dx.doi.org/10.1016/j.ijantimicag.2006.01.004.
16. Landman D, Bratu S, Quale J. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol 58:1303-1308. http://dx.doi.org/10.1099/jmm.0.012575-0.
17. Castanheira M, Becker HK, Rhomberg PR, Jones RN. 2014. Effect of the β-lactamase inhibitor RPX7009 combined with meropenem tested against a large collection of KPC-producing Enterobacteriaceae, abstr C-777. Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014.
18. Castanheira M, Rhomberg PR, Watters A, Jones RN. 2014. In vitro activity of meropenem/RPX7009, a carbapenem/β-lactamase inhibitor combination tested against contemporary populations of Enterobacteriaceae and KPC-producing strains. Open Forum Infect Dis 1(Suppl 1):S110.
19. Tarazi Z, Sabet M, Rubio-Aparicio D, Nolan T, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC. 2014. Efficacy of simulated human exposures of Carbavance (meropenem-RPX7009) against carbapenem-resistant Enterobacteriaceae in an in vitro hollow fiber model, abstr F-959. Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014.
20. Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC. 2014. In vivo efficacy of carbavance (meropenem/RPX7009) against KPC-producing Enterobacteriaceae, abstr F-958. Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014.
21. Doumith M, Ellington MJ, Livermore DM, Woodford N. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63:659-667. http://dx.doi.org/10.1093/jac/dkp029.
22. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. 2012. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline β avibactam (NXL104). J Antimicrob Chemother 67:1354-1358. http://dx.doi.org/10.1093/jac/dks079.